- How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen
The disease is characterized by the accumulation of small, mature CD5- and CD23-positive mature B cells, usually in the blood, BM and secondary lymphoid organs, including lymph nodes and spleen
- CD5 and B lymphocyte responses: multifaceted effects through multitudes . . .
In a series of experiments, we confirmed that CD5 directly modulates B lymphocyte responses 3 Using cell transfection, we observed that CD5-mediated induction of mitogen-activated protein kinase (MAPK) Erk1 2 activation is key to inducing IL-10 production
- Pathology Outlines - CD5
The positive expression of CD5, FOXN1, PAX8 and CD117 supports a diagnosis of thymic carcinoma and argues against squamous cell carcinoma of the lung (with low to negative expression for these markers in lung SCC)
- Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B . . .
CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by a poor prognosis and frequent central nervous system (CNS) relapse
- CD5 Positive B Cell Lymphoproliferative Disorder Insights
CD5 positive B cell lymphoproliferative disorder refers to a class of conditions that involve the abnormal growth of B cells expressing CD5 This protein is frequently associated with certain lymphoproliferative malignancies Understanding this disorder is crucial for effective diagnosis and treatment
- CD5‐positive chronic B‐cell . . . - Wiley Online Library
We studied patients with CD5+B-CLPD to (1) more completely define the clinical features and pathology of CD5+B-CLPD, (2) compare these features to patients presenting with typical CLL, and (3) test the hypothesis that a subset of patients with CD5+B-CLPD could have a unique B-cell malignancy
- CD5-positive high-grade B-cell lymphoma with - American Society of . . .
Next-generation sequencing identified multiple mutations, including NFKB2 (c 1719_1754del, p E576_P587del, VAF: 19%), ARID1A (c 1413C>G, p Y471, VAF: 35%), BCL2 (multiple), IKZF3 (c 485T>G, p L162R, VAF: 10%), and MYC (multiple) These findings support a diagnosis of CD5-positive, high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements
- CD5-positive chronic B-cell lymphoproliferative disorders: Diagnosis . . .
We studied patients with CD5+B-CLPD to 1) more completely define the clinical features and pathology of CD5+B-CLPD, 2) compare these features to patients presenting with typical CLL, and 3) test the hypothesis that a subset of patients with CD5+B-CLPD could have a unique B-cell malignancy
|